Intraocular pressure-lowering efficacy and safety of bimatoprost 0.03% therapy for primary open-angle glaucoma and ocular hypertension patients in China

Table 2 Patient characteristics at baseline

Characteristic^a	All enrolled N = 263	A N = 89	B N = 33	C N = 67	D N = 18	E N = 33	Undefined N = 23
Age (years)	48.7 ± 16.6	44.6 ± 15.3	48.2 ± 20.5	52.1 ± 15.7	52.8 ± 12.5	54.1 ± 18.2	44.4 ± 14.7
Sex (male)	155 (58.9%)	47 (52.8%)	19 (57.6%)	45 (67.2%)	6 (33.3%)	22 (66.7%)	16 (69.6%)
Diagnosis
POAG	214 (81.4%)	53 (59.6%)	31 (93.9%)	64 (95.5%)	18 (100.0%)	32 (97.0%)	16 (69.6%)
OHT	49 (18.6%)	36 (40.4%)	2 (6.1%)	3 (4.5%)	0	1 (3.0%)	7 (30.4%)
Enrolled eye (OD)	141 (53.6%)	44 (49.4%)	17 (51.5%)	36 (53.7%)	13 (72.2%)	17 (51.5%)	14 (60.9%)
History of laser treatment for glaucoma	25 (9.5%)	7 (7.9%)	6 (18.2%)	6 (9.0%)	3 (16.7%)	1 (3.0%)	2 (8.7%)
History of surgical treatment for glaucoma	57 (21.8%)	10 (11.5%)	7 (21.2%)	14 (20.9%)	8 (44.4%)	11 (33.3%)	7 (30.4%)
Comorbidities	34 (12.9%)	4 (4.5%)	11 (33.3%)	10 (14.9%)	2 (11.1%)	7 (21.2%)	0

^aContinuous data are presented as mean ± SD and categorical data are presented as n (%).
POAG primary open-angle glaucoma; OHT ocular hypertension. Group A: treatment-naive patients received in-trial bimatoprost monotherapy; Group B: pretrial PG mono-treated patients received in-trial switch monotherapy with bimatoprost; Group C: pretrial non-PG mono- or combination-treated patients received in-trial switch monotherapy with bimatoprost; Group D: pretrial PG combination-treated patients received in-trial PM replacement with bimatoprost; Group E: pretrial non-PG mono- or combination-treated patients received bimatoprost as an adjunctive agent in addition to the previous treatment modality.

ISSN: 1471-2415